glp-1 and dual glp-1/gip receptor agonists Fair Allocation of GLP-1–GIP GLP‑1 Receptor Agonists and Preclinical
Description
eClinicalMedicine 72 , 102624 (2024)
Given the relatively smaller reduction in body weight (9.4%) in the SELECT trial compared to previous RCTs: 14.9% in STEP1 (BMI 37.86.7 kg/m 2 ) [16] and 13.2% STEP6 (BMI 31.9 kg/m 2 ) [49], pleiotropic effects of semaglutide may contribute to the overall CV risk reduction [25,37]
These findings underscore the importance of careful monitoring to address these potential risks
rgaard, A
(Lausanne) 13 , 880503 (2022)
Gastrointestinal autonomic neuropathy in diabetes
